Trytosaveabit
OP
:
Benzinga· 2 mins ago Citius Pharma Announces LYMPHIR Is Approved By The FDA For The Treatment Of Adult Patients With Relapsed Or Refractory Stage 1-3 Cutaneous T-Cell Lymphoma
Trytosaveabit
OP
萬軍無兵策天鳳
:
Yup! SS’s attacking certain tickers so hard, over and over ends up getting people to not trust/be interested anymore! Sad but it happens
$Citius Pharmaceuticals (CTXR.US)$$Citius Oncology (CTOR.US)$ Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Tuesday, 7th January at 8:08 am CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
$Citius Oncology (CTOR.US)$ Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Monday, 6th January at 7:50 am CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alter...
Citius Oncology Stock Forum
Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
PR Newswire· 4 mins ago
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
📊⚡️📊
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alter...
📊⚡️📊
📊⚡️📊
No comment yet